News & Updates
Filter by Specialty:
Cancer therapy takes a toll on women’s sexual health
In women being treated for cervical cancer, chemotherapy and radiotherapy appear to have a substantial and lasting negative effect on sexual health, including satisfaction and desire, as shown in a descriptive cross-sectional study conducted in Brazil.
Cancer therapy takes a toll on women’s sexual health
06 May 2025
Letrozole-abemaciclib plus metformin shows promise in endometrial cancer treatment
Adding metformin to letrozole and abemaciclib does not cause serious safety concerns and may even encourage favourable responses among patients with oestrogen receptor (ER)-positive recurrent endometrial cancer (EC), according to a phase II study presented at SGO 2025.
Letrozole-abemaciclib plus metformin shows promise in endometrial cancer treatment
05 May 2025
Progestin-only contraceptives may pose NAFLD risk among women with GDM history
The use of progestin-only contraceptives may put women with a history of gestational diabetes mellitus (GDM) at risk of nonalcoholic fatty liver disease (NAFLD), as shown in a small prospective study.
Progestin-only contraceptives may pose NAFLD risk among women with GDM history
25 Apr 2025
Is there a need for invasive urodynamics to manage OAB in women?
Augmenting comprehensive clinical assessment (CCA) with invasive urodynamic investigations does not appear to benefit women with refractory overactive bladder (OAB) symptoms in the FUTURE* study presented at EAU25.
Is there a need for invasive urodynamics to manage OAB in women?
23 Apr 2025
3-year RUBY data support add-on dostarlimab as frontline Tx for endometrial cancer
At the second interim analysis of part 1 of the phase III RUBY study, updated duration of response (DoR) findings suggest that women with primary advanced or recurrent endometrial cancer who have achieved a response with the combination regimen comprising dostarlimab and carboplatin-paclitaxel (CP) have substantially improved DoR.